EXICURE, INC. (XCUR) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-10

Key Insights

Exicure, Inc. appointed Yoontae Han to its Board of Directors and Dongho Lee as Chair of the Audit Committee, strengthening the company's governance and oversight.
The company appointed Young Seung Ko as its new Chief Operating Officer, bringing over 20 years of experience in enterprise software, data infrastructure, and public company operations.
Exicure amended its executive services agreement with Innocircle Advisors to include the services of the Chief Operating Officer, potentially indicating an increased focus on operational execution.

Want the newest filings?

This analysis covers the filing from 2026-04-10. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-27

Sangjin Yeo has resigned from Exicure's Board of Directors and Audit Committee, effective March 27, 2026. This resignation does not appear to be due to any disagreements with the company's operations, policies or practices.
The departure of a board member could signal potential changes in the company's leadership or strategic direction, which may impact investor sentiment.
Investors should monitor any further developments or announcements related to Yeo's resignation and any potential implications for Exicure's future.

Filed: 2026-03-25

Exicure, Inc. announced its financial and operational results for the year ended December 31, 2025, as disclosed in the press release.
The company's performance during this period may be of interest to investors and could impact the stock price.
Investors should review the press release and financial statements for further details on the company's financial condition and operations.

Filed: 2026-01-22

Exicure, Inc. achieved the first contractual milestone under its License and Collaboration Agreement with GPCR Therapeutics Inc., receiving a $1 million payment for completing a Phase 2 clinical trial of its novel stem cell mobilizer.
The milestone achievement reflects continued progress in the development and advancement of the small molecule CXCR4 inhibitor, Burixafor (GPC-100), and triggers a future sublicensing income-sharing ratio, indicating increased participation and commitment to the long-term success of the program.
The 8-K filing provides transparency on a significant operational milestone, which could positively impact investor sentiment and the company's future financial performance.

Other reports for EXICURE, INC.

Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.